Advertisement

Topics

Novartis’ Wet AMD Drug Meets Primary and Key Secondary Endpoints in Two Late-Stage Studies

15:39 EDT 20 Jun 2017 | Speciality Pharma Journal

Basel, June 20, 2017 – Novartis, the global leader in Ophthalmology, today reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These pivotal studies enrolled more than 1,800 patients with neovascular age-related macular …

Original Article: Novartis’ Wet AMD Drug Meets Primary and Key Secondary Endpoints in Two Late-Stage Studies

NEXT ARTICLE

More From BioPortfolio on "Novartis’ Wet AMD Drug Meets Primary and Key Secondary Endpoints in Two Late-Stage Studies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...